The End of Chemo Treatment, Relief or Anxiety?

There is no question that completing a course of chemotherapy treatment is a milestone in the life of a patient. Tomorrow, my 89-yr-old mother will receive her sixth and final dose of chemotherapy for lymphoma. She was initially hesitant about chemo and the effects it would have on her but eventually agreed to go through treatment. As she approaches her final dose, I honestly wonder whether it’s time for celebration or anxiety.

Chemotherapy gives the patient the ability to confront cancer cells head on. The possible side effects are a reminder that the toxins are doing their job and crushing the cancer cells. The chemotherapy has been a ‘body guard’ of sorts for my Mom, attacking her tumor with a prescribed course of action. After tomorrow, my Mom will part ways with this powerful partner and protector and be on her own. Without the toxic soldiers on her side, I imagine she might feel vulnerable, anxious, and alone. My role as her caregiver and advocate will change again as I encourage and support her as she gets back to living life as a cancer-free woman.

My Mom’s chemo ride was rough at times, but she kept her eye on the finish line. Now it’s time to enjoy life and savor moments with family and loved ones. Congratulations Mom, let’s choose celebration.

Susan M. Beausang

4women.com

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap